Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/80732
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorSchool of Nursing-
dc.creatorMolassiotis, A-
dc.creatorSuen, LKP-
dc.creatorCheng, HL-
dc.creatorMok, TSK-
dc.creatorLee, SCY-
dc.creatorWang, CH-
dc.creatorLee, P-
dc.creatorLeung, H-
dc.creatorChan, V-
dc.creatorLau, TKH-
dc.creatorYeo, W-
dc.date.accessioned2019-05-28T01:08:58Z-
dc.date.available2019-05-28T01:08:58Z-
dc.identifier.issn1534-7354en_US
dc.identifier.urihttp://hdl.handle.net/10397/80732-
dc.language.isoenen_US
dc.publisherSAGE Publicationsen_US
dc.rights© The Author(s) 2019 Article reuse guidelines: sagepub.com/journals-permissionsen_US
dc.rightsCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage)en_US
dc.rightsThe following publication Molassiotis, A., Suen, L. K. P., Cheng, H. L., Mok, T. S. K., Lee, S. C. Y., Wang, C. H., … Yeo, W. (2019). A randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Integrative Cancer Therapies, 18, 1-12 is published by Sage and is available at https://dx.doi.org/10.1177/1534735419836501en_US
dc.subjectAcupunctureen_US
dc.subjectChemotherapy-induced peripheral neuropathyen_US
dc.subjectCanceren_US
dc.subjectNeurotoxicityen_US
dc.subjectQuality of lifeen_US
dc.subjectPainen_US
dc.titleA randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathyen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage1en_US
dc.identifier.epage12en_US
dc.identifier.volume18en_US
dc.identifier.doi10.1177/1534735419836501en_US
dcterms.abstractPurpose: Chemotherapy-induced peripheral neuropathy is a complex side effect with few available treatment options. The aim of the study was to test the effectiveness of an 8-week course of acupuncture in the management of chemotherapy induced peripheral neuropathy in cancer patients who were receiving or had received neurotoxic chemotherapy.-
dcterms.abstractMethods: Randomized assessor-blinded controlled trial with 2 arms; one arm received acupuncture twice weekly for 8 weeks, while the other arm was a wait-list control group receiving only standard care. Primary outcome was pain intensity and interference over the past week using the Brief Pain Inventory at the end of the intervention. Secondary outcomes included clinical assessment (CTCAE [Common Toxicity Criteria for Adverse Events] grading and Total Neuropathy Score–Clinical Version) and nerve conduction studies; and patient-reported outcome measures (Functional Assessment of Cancer Therapy–Gynecologic Oncology Group–Neurotoxicity Quality of Life scale and Symptom Distress Scale) assessed at baseline, end of treatment (8 weeks), week 14, and week 20 from the beginning of treatment.-
dcterms.abstractResults: Eighty-seven patients were randomized to the experimental arm (n = 44) and to the standard care wait-list control arm (n = 43). Significant changes at 8 weeks were detected in relation to primary outcome (pain), the clinical neurological assessment, quality of life domains, and symptom distress (all P < .05). Improvements in pain interference, neurotoxicity-related symptoms, and functional aspects of quality of life were sustained in the 14-week assessment (P < .05), as were physical and functional well-being at the 20-week assessment (P < .05).-
dcterms.abstractConclusions: Acupuncture is an effective intervention for treating chemotherapy-induced peripheral neuropathy and improving patients’ quality of life and experience with neurotoxicity-related symptoms with longer term effects evident.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationIntegrative cancer therapies, 2019, v. 18, p. 1-12-
dcterms.isPartOfIntegrative cancer therapies-
dcterms.issued2019-
dc.identifier.isiWOS:000462300700001-
dc.identifier.pmid30905173-
dc.identifier.ros2018000070-
dc.identifier.eissn1552-695Xen_US
dc.description.validate201905 bcrcen_US
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumbera0307-n06en_US
dc.description.pubStatusPublisheden_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Molassiotis_Assessor-Blinded_Trial_Assess.pdf296.95 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

114
Last Week
0
Last month
Citations as of Apr 14, 2024

Downloads

114
Citations as of Apr 14, 2024

SCOPUSTM   
Citations

52
Citations as of Apr 19, 2024

WEB OF SCIENCETM
Citations

48
Citations as of Apr 18, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.